Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical use for expanded peripheral blood stem cells.

T A Bock1, S Scheding, W Brugger

  • 1Department of Hematology, Oncology, and Immunology, University of Tübingen, Germany.

Bailliere'S Best Practice & Research. Clinical Haematology
|September 23, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation.

Bone marrow transplantation·2019
Same author

[Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example].

Pneumologie (Stuttgart, Germany)·2018
Same author

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC).

Journal of cancer research and clinical oncology·2018
Same author

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Leukemia·2017
Same author

Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma.

Leukemia·2017

Peripheral blood progenitor cells (PBPC) are increasingly used for hematopoietic restoration after chemotherapy. Ex vivo expansion techniques offer diverse clinical applications, including tumor purging, enhanced transplantation, and gene therapy.

Area of Science:

  • Hematology
  • Cell Therapy
  • Immunology

Background:

  • Peripheral blood progenitor cells (PBPC) are crucial for restoring hematopoiesis after high-dose chemotherapy.
  • Ex vivo manipulation techniques for hematopoietic cells have advanced significantly.
  • The clinical utility of PBPC expansion is growing.

Purpose of the Study:

  • To review the diverse clinical applications of ex vivo expanded peripheral blood progenitor cells.
  • To highlight the potential of enhanced PBPC expansion strategies.
  • To discuss the role of ex vivo generated cells in immunotherapy and gene therapy.

Main Methods:

  • Review of existing literature on ex vivo expansion protocols for PBPC.
  • Analysis of clinical applications and potential future directions.

Related Experiment Videos

  • Synthesis of data on quantitative expansion, allogeneic transplantation, and cell-based therapies.

    • Main Results:

    • Ex vivo expansion enables quantitative augmentation of PBPC for various clinical needs.
    • Strategies for tumor cell purging and generating sufficient cell numbers for transplantation are being developed.
    • Allogeneic transplantation of megadoses of PBPC can overcome immunological barriers and expand donor pools.
    • Ex vivo generated cells show promise in immunotherapy and as vehicles for genetic therapy.

    Conclusions:

    • Ex vivo expansion of PBPC is a versatile platform with broad clinical implications.
    • Further development of these techniques can significantly impact cancer treatment and genetic therapies.
    • PBPC expansion holds promise for improving patient outcomes and expanding treatment options.